| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 20/12/2024 | 23:00 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 25/11/2024 | 23:06 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 12/11/2024 | 22:05 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 12/08/2024 | 14:30 | GlobeNewswire Inc. | Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 02/07/2024 | 14:30 | GlobeNewswire Inc. | Telomir Pharmaceuticals Added to Membership of Russell 3000 and Russell Microcap Indexes | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 17/06/2024 | 22:10 | GlobeNewswire Inc. | Telomir Pharmaceuticals Scientific Advisor to Participate in Drug Information Association 2024 Global Annual Meeting Panel | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 30/05/2024 | 14:30 | GlobeNewswire Inc. | Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1 | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 24/05/2024 | 15:30 | GlobeNewswire Inc. | New to The Street TV Announces Episode 575 with its Four Business Guest Interviews, Airs as Sponsored Programming on Bloomberg TV, Saturday, May 25, 2024, at 6:30 PM ET | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 16/05/2024 | 15:30 | GlobeNewswire Inc. | Telomir Pharmaceuticals, Inc. Signs Media Deal with New to The Street for Network Interview Broadcasts, Billboards, and TV Commercial Support | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 16/04/2024 | 14:30 | GlobeNewswire Inc. | Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C. | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 02/04/2024 | 14:30 | GlobeNewswire Inc. | Telomir Pharmaceuticals’ Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024 | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 29/03/2024 | 21:44 | GlobeNewswire Inc. | UPDATE – Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 26/03/2024 | 13:30 | GlobeNewswire Inc. | Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 22/03/2024 | 13:30 | GlobeNewswire Inc. | Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 14/03/2024 | 13:30 | GlobeNewswire Inc. | Telomir Pharmaceuticals Uses AI Testing Models to Show its Lead Product Candidate’s Potential in DNA Age Reversal Science | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 07/03/2024 | 14:30 | GlobeNewswire Inc. | Telomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conference | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 05/03/2024 | 14:30 | GlobeNewswire Inc. | Michael F. Roizen, MD to Increase Activities with Telomir Pharmaceuticals as Special Advisor on Age Reversal | NASDAQ:TELO | Telomir Pharmaceuticals Inc |
| 13/02/2024 | 22:05 | GlobeNewswire Inc. | Telomir Pharmaceuticals Announces Closing of Initial Public Offering | NASDAQ:TELO | Telomir Pharmaceuticals Inc |